Who are Zura Bio Limited's main suppliers?

Zura Bio Limited (ZURA) key suppliers include: ATHANOR, LONZA-SALES-AG, Pfizer Inc., Pfizer Inc., WUXI-BIOLOGICS and 4 more. View the full supplier network at chainsifter.com/chain/ZURA.

Who are Zura Bio Limited's major customers?

Zura Bio Limited (ZURA) key customers include: Eli Lilly and Company, Eli Lilly and Company, Sanofi, Sanofi, BAFFX17-LTD and 6 more. View the full customer network at chainsifter.com/chain/ZURA.

What sector is Zura Bio Limited in?

Zura Bio Limited (ZURA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Zura Bio Limited Supplier List (ZURA): 9 Verified Suppliers

9Suppliers

11Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Zura Bio Limited (ZURA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

4Distinct source URLs

10High confidence

0.759Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Zura Bio Limited Suppliers

Ticker	Name	Confidence	Evidence
ATHANOR	ATHANOR	90%	the Company agreed to pay an amount equal to 2% of Net Sales (as defined in the Athanor Agreement) for the Product (as defined in the Athanor Agreement) to the extent such Net Sales (collectively, th…
LONZA-SALES-AG	LONZA-SALES-AG	90%	Pursuant to the terms of the Lonza License, the Company has a license fee of $ 0.4 million due to Lonza annually in the fourth quarter as a result of manufacturing drug substance with a third party o…
PFE	Pfizer Inc.	90%	Reciprocal relationship from PFE graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from PFE grap…
PFE	Pfizer Inc.	90%	We are party to a license agreement with Pfizer under which we were granted rights to certain patents, know-how and technology that are important and necessary to our business, including for crebankitug.
WUXI-BIOLOGICS	WUXI-BIOLOGICS	90%	If the Company manufactures all of its commercial supplies of bulk drug product for WuXi Biologics Licensed Products with a manufacturer other than WuXi Biologics or its affiliates, the Company is re…
BAFFX17	BAFFX17	80%	the Company and its subsidiaries, on the one hand, and Stone Peach or BAFFX17, on the other hand, including the extinguishment of any and all rights or claims Stone Peach or BAFFX17 may have under al…
STONE-PEACH	STONE-PEACH	80%	the Company and its subsidiaries, on the one hand, and Stone Peach or BAFFX17, on the other hand, including the extinguishment of any and all rights or claims Stone Peach or BAFFX17 may have under al…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZURA graph: nst such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our pr…
SNYNF	Sanofi	72%	nst such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could ad…

Zura Bio Limited Customers

Ticker	Name	Confidence	Evidence
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ZURA graph: e limited or incomplete, and statemen…
LLY	Eli Lilly and Company	72%	e limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. All forward-loo…
SNYNF	Sanofi	72%	nst such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could ad…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from SNYN…
BAFFX17-LTD	BAFFX17-LTD	62%	December 31, 2025 2024 Accrued research and development costs $ 6,575 $ 7,100 Accrued 2023 Lilly License costs — 9,500 Accrued bonus 3,319 1,713 Accounts payab…
EMERGING-GROWTH-COMPANY	EMERGING-GROWTH-COMPANY	62%	ell as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Pa…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	ries. Overview We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating c…
LONZA-SALES-AG	LONZA-SALES-AG	62%	ective thresholds of net sales of products developed from the licensed compound; and (b) an annual earned royalty at a marginal royalty rate in the mid-single to low-double digits, with increasing ra…
STONE-PEACH-PROPERTIES-LLC	STONE-PEACH-PROPERTIES-LLC	62%	ective thresholds of net sales of products developed from the licensed compound; and (b) an annual earned royalty at a marginal royalty rate in the mid-single to low-double digits, with increasing ra…
Z33-BIO-INC	Z33-BIO-INC	62%	necessitate the selection of a new manufacturer and require additional stability studies thus 13 Table of Contents impacting our ability to supply torudokimab to meet future demand. See the risk fact…
ZB17-LLC	ZB17-LLC	62%	necessitate the selection of a new manufacturer and require additional stability studies thus 13 Table of Contents impacting our ability to supply torudokimab to meet future demand. See the risk fact…

Zura Bio Limited Debt Obligations

Instrument	Description	Confidence	Evidence
ZURA-DEBT-13792	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
ZURA-DEBT-13791	Warrants outstanding: 0.001	90%	xbrl warrant detail from xbrl 2025-09-30.

Zura Bio Limited Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zura Bio Limited.

Zura Bio Limited Ownership

Holder	Name	Confidence	Evidence
ZURA-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC	SUVRETTA CAPITAL MANAGEMENT, LLC	90%	13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 95 tracked holders.

Zura Bio Limited Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ACIU	AC Immune SA	100.00	2
IMNM	Immunome, Inc.	100.00	2
BYSI	BeyondSpring Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
ACRS	Aclaris Therapeutics, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
INCY	Incyte Corporation	100.00	2

Zura Bio Limited Supply Chain